not yet imo breaking system
the exclusive joint development and license agreement across 10yrs in 'australia' for the insomnia market is 10x 235/255 million annually at 2024 numbers
I believe we'll find that US 3 million is a down payment for that exclusive access on the US 16 million development milestone payments prior to commercialisation in Aus.
Dr Paul has negotiated a solid agreement it seems - Sandoz Group AG understand the 'opportunity' this drug if successful presents
gotta let the details soak out across markets
just my view of course
not yet imo breaking system the exclusive joint development and...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.86M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.6¢ | 0.4¢ | $28.1K | 5.620M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 43 | 40990100 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 450000 | 1 |
View Market Depth
| Last trade - 15.47pm 31/07/2025 (20 minute delay) ? |
| AVE (ASX) Chart |